EN
Home/United States/Blog/Zepbound for sleep apnea: who qualifies, and why do insurers cover it differently?
USUnited States Coverage and eligibility

Zepbound for sleep apnea: who qualifies, and why do insurers cover it differently?

The FDA approval, the two SURMOUNT-OSA trials, what a sleep study has to show, and why a sleep apnea diagnosis changes what Medicare, Medicaid and employer plans can pay for.

GLP Guidebook teamPublished Oct 12, 20266 min read10 sourcesWritten from published sources

Written for the United States. Reading from India? India version

The short answer

Since December 2024, Zepbound (tirzepatide) has been FDA-approved for moderate-to-severe obstructive sleep apnea in adults with obesity. Because this is a medical condition rather than weight loss, Medicare drug plans can cover it. One large pharmacy benefit manager asks for a sleep test showing 15 or more breathing pauses an hour and a BMI of 30 or more.

Key takeaways

  • The FDA approved Zepbound in December 2024 for moderate-to-severe obstructive sleep apnea in adults with obesity, calling it the first drug treatment option for certain patients.1
  • In two 52-week trials, breathing pauses fell by 25 to 29 an hour on Zepbound, against about 5 an hour on placebo.2,3
  • Medicare drug plans can cover GLP‑1s for sleep apnea, unlike weight loss alone, and people with moderate-to-severe sleep apnea are excluded from the GLP‑1 Bridge.4,5
  • One large pharmacy benefit manager covers Zepbound for sleep apnea with a sleep test showing at least 15 events an hour and a BMI of 30 or more.6
  • In the sleep apnea trials, pancreatitis was confirmed at 0.84 cases per 100 years of treatment on Zepbound, against none on placebo.2
Before you go further
  • Only a clinician can diagnose sleep apnea, usually with a sleep test. This post describes the label and payers’ rules; it can’t say you qualify.
  • Prices are the maker’s published prices. We don’t name or link to any seller.
  • Zepbound carries real risks: see below and our side effects guide.
On this page
  1. What did the FDA approve Zepbound for in sleep apnea?
  2. What did the sleep apnea trials show?
  3. Who qualifies, and what does an insurer ask for?
  4. Why can Medicare cover Zepbound for sleep apnea but not for weight?
  5. What does Zepbound cost if it isn’t covered?
  6. Questions people ask
  7. How we researched this
  8. Sources

What did the FDA approve Zepbound for in sleep apnea?

For moderate-to-severe obstructive sleep apnea in adults with obesity, alongside a reduced-calorie diet and more physical activity, approved on December 20, 2024.1

Obstructive sleep apnea (OSA) happens when the upper airway becomes blocked during sleep, causing pauses in breathing.1 Its severity is measured by the apnea-hypopnea index (AHI): the number of full or partial breathing pauses per hour of sleep.3 In the trials, moderate meant 15 to 30 an hour and severe meant 30 or more.2

The FDA called it “the first drug treatment option for certain patients with obstructive sleep apnea”.1 The label’s maintenance dose for OSA is 10 or 15 mg a week, after starting at 2.5 mg.2 Zepbound’s other approval is for weight: see Zepbound vs Wegovy.

What did the sleep apnea trials show?

Over 52 weeks, breathing pauses fell by 25 to 29 an hour on Zepbound against about 5 on placebo, and about half reached remission or mild sleep apnea without symptoms.2

The SURMOUNT-OSA program ran two trials in 469 adults with obesity (BMI 30 or more) and moderate-to-severe OSA, without diabetes. Study 5 enrolled people not using a breathing machine (PAP, such as CPAP); Study 6 enrolled people who were. Eli Lilly paid for it.2,3

SURMOUNT-OSA
Reached remission or mild sleep apnea without symptoms
Adults with obesity and moderate-to-severe OSA · 52 weeks · per 100 people
No PAP, Zepbound42
No PAP, placebo16
On PAP, Zepbound50
On PAP, placebo14
Remission or mild sleep apnea without symptoms: fewer than 5 events an hour, or 5 to 14 with little daytime sleepiness. US label, Table 9.2
  • Breathing pauses (Study 5, no PAP): down 25.3 an hour on Zepbound, against 5.3 on placebo, from about 51 at the start.2
  • Breathing pauses (Study 6, on PAP): down 29.3 an hour, against 5.5.2
  • Weight: down 17.7% and 19.6% on Zepbound, against 1.6% and 2.3% on placebo.2

The label says the trials did not test when, or whether, people on PAP should stop using it.2 That is a decision for your sleep clinician.

RisksThe risks, in brief
  • Stomach effects. In the main trials, about 25 to 29 in 100 people on Zepbound felt sick, against about 8 in 100 on a dummy injection.2 It mostly comes while the dose goes up.
  • Gallstones were reported in 11 in 1,000 on Zepbound, against 10 in 1,000 on placebo, with gallbladder inflammation in 7 in 1,000 against 2 in 1,000.2
  • Pancreatitis (an inflamed pancreas): severe stomach pain that won’t go away and may spread to the back. The labels say to stop the medicine if it is suspected.2
  • Thyroid warning. The labels carry a boxed warning: these medicines are not for people with a personal or family history of medullary thyroid cancer (MTC) or MEN 2, a rare inherited condition that causes gland tumors.2
  • Dehydration from vomiting or diarrhea can harm the kidneys. Tell the team before any surgery or sedation, because a slower-emptying stomach raises the risk of breathing in food or fluid.2
  • Pregnancy. Zepbound can make birth-control pills less reliable for about 4 weeks after starting and after each dose step.2
Full detail in our side effects guide →
Get help now: call 911 or go to the ER for severe stomach pain that won’t go away, with or without vomiting (it can be pancreatitis), or for swelling of the face or throat or trouble breathing. For a possible overdose, Poison Control is 1-800-222-1222.2,7

Who qualifies, and what does an insurer ask for?

The label covers adults with obesity and moderate-to-severe OSA; one large pharmacy benefit manager asks for a sleep test showing 15 or more events an hour and a BMI of 30 or more.2,6

A pharmacy benefit manager (PBM) runs drug benefits for many employer plans. One of the largest publishes these criteria for Zepbound in OSA, with documents required:6

  • a diagnosis of moderate to severe OSA with an AHI of at least 15 an hour, on a lab sleep study (polysomnography) or a home sleep apnea test;
  • a current BMI of 30 or more;
  • use alongside a reduced-calorie diet and more physical activity.

Approval lasts 6 months at first. Renewal, for 12 months, asks for a sleep test on file, fewer OSA symptoms and a maintenance dose.6 For weight, the same PBM wants 6 months in a weight program and 5% weight loss to renew. The OSA route has neither rule.6 Your own plan’s rules may differ: see prior authorization, step by step.

At 5 ft 9 in (175 cm), a BMI of 30 is about 203 lb (92 kg).

Free toolGet ready for the appointment

Build your own list of questions to take to your doctor. No sign-up.

Make my list

Why can Medicare cover Zepbound for sleep apnea but not for weight?

Medicare is barred by law from covering drugs for weight loss, but Part D plans can cover GLP‑1s for other approved uses, including sleep apnea.4

KFF says Part D plans can cover GLP‑1s for “type 2 diabetes, cardiovascular disease risk reduction, or sleep apnea”.4 Each plan still decides its own formulary and prior authorization.

The $50 Medicare GLP‑1 Bridge is for weight only. People with moderate-to-severe sleep apnea are not eligible for it and are told to contact their drug plan, which “may already cover a GLP‑1 drug”.5 See the Medicare GLP‑1 Bridge.

Medicaid follows a similar line. KFF says states must cover drugs for approved uses such as sleep apnea, while coverage for obesity is optional: see Medicaid and GLP‑1s.8

What does Zepbound cost if it isn’t covered?

Lilly’s self-pay prices are $299 a month at 2.5 mg, $399 at 5 mg and $449 at the 10 and 15 mg OSA doses, if each refill comes within 45 days.9

Miss the 45-day refill window and the 10 and 15 mg price is $699 a month.9 With commercial coverage, Lilly’s savings card can bring a pen fill to “as little as $25”, up to $1,300 a year. It isn’t for Medicare or Medicaid members.10 A full year is worked out in GLP‑1 costs without insurance.

Questions people ask

Does insurance cover Zepbound for sleep apnea?

Many plans can, with prior authorization. One large PBM’s criteria ask for a sleep test showing an AHI of 15 or more and a BMI of 30 or more.6

Does Medicare cover Zepbound for sleep apnea?

Part D plans can cover GLP‑1s for sleep apnea, unlike for weight loss alone. Each plan sets its own rules.4

Do I need a sleep study to get Zepbound for sleep apnea?

The label covers moderate-to-severe OSA, which is diagnosed with a sleep test. One large PBM accepts a lab study or a home sleep apnea test.2,6

Can Zepbound replace my CPAP?

The label says the trials did not test when or whether people on PAP should stop. Ask your sleep clinician.2

What dose of Zepbound is used for sleep apnea?

The label’s maintenance dose for OSA is 10 or 15 mg once a week, after starting at 2.5 mg and stepping up.2

How we researched this

We used the FDA’s approval announcement, the current US Zepbound label, the SURMOUNT-OSA paper and KFF’s Medicare and Medicaid briefs, all checked on October 12, 2026.1,2,3,4,8

Insurer criteria are one large pharmacy benefit manager’s published document, used as an example. We did not collect other plans’ criteria. The BMI example is our arithmetic.6

Before you move on

  • Get a copy of your sleep study and your AHI.
  • Ask your plan whether it covers Zepbound for OSA.
  • Ask your sleep clinician about PAP before changing anything.
  • If on Medicare, ask your Part D plan, not the Bridge.
  • Know the warning signs of pancreatitis.
Doctor questionsBMI and waistSide effects and risks

More from the US blog

USUnited StatesZepbound vs Wegovy: which loses more weight, and how do side effects, cost and coverage compare?USUnited StatesDoes Medicare cover Wegovy or Zepbound? The $50 Medicare GLP‑1 Bridge explainedUSUnited StatesHow do you get Zepbound or Wegovy covered by insurance? Prior authorization, step by step
About GLP Guidebook

The monthly US update

An independent guide to GLP‑1 medicines. We don’t sell medicines, take drug-company money, earn commissions or link to any provider. Once a month: FDA approvals and warnings, Medicare and Medicaid changes, and makers’ price changes. How we write

Was this post easy to understand?

Sources

  1. FDA. FDA approves first medication for obstructive sleep apnea. Press release, December 20, 2024. Link
  2. Eli Lilly. Zepbound (tirzepatide): US prescribing information. Revised 8/2026. Link
  3. Malhotra A, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity (SURMOUNT-OSA). N Engl J Med 2024;391:1193-1205. doi:10.1056/NEJMoa2404881. PMID 38912654. Funded by Eli Lilly. Link
  4. KFF. What to know about the BALANCE Model for GLP-1s in Medicare and Medicaid and the Medicare GLP-1 Bridge. May 11, 2026. Link
  5. Medicare.gov. Medicare GLP-1 Bridge: GLP-1 drugs for $50 a month (fact sheet). CMS Product No. 12234, June 2026. Link
  6. CVS Caremark. Tirzepatide prior authorization criteria with quantity limit, reference 6947-C (pharmacy benefit manager criteria document). Checked Oct 12, 2026. Link
  7. Poison Control (National Capital Poison Center). Poison help line 1-800-222-1222. Link
  8. KFF. Medicaid coverage of and spending on GLP-1s, including Figure 1 state map and notes. January 16, 2026. Link
  9. Eli Lilly. LillyDirect Zepbound self-pay page (vial and KwikPen prices; regular prices if not refilled within 45 days), lilly.com/lillydirect. Checked Oct 12, 2026. Not linked because the page sells medicine.
  10. Eli Lilly. Zepbound coverage and savings, for health care providers. Checked Oct 12, 2026. Link

Last checked Oct 12, 2026 · Next review due Apr 12, 2027 · Report an error

How this post was made. Written by the GLP Guidebook team from the sources above. It’s general information, not medical advice. Talk to your doctor, pharmacist or prescriber before starting, stopping or changing any medicine. We don’t sell, prescribe or recommend any brand or provider. How we write